In multiple myeloma, a high-dose conditioning treatment prior to stem cell transplant
Prescribing Information Important Safety Information

     

    Acrotech Biopharma, LLC. Trademark Policy

    The tradenames, trademarks, service marks, logos, icons and trade dress of Acrotech Biopharma, LLC, appearing on this website may not be used in any manner by users of this website without the express prior written permission of Acrotech Biopharma, LLC. Such tradenames, trademarks, service marks, logos, icons and trade dress, include, without limitation, Acrotech Biopharma, LLC®, EVOMELA®, the Acrotech Biopharma and the EVOMELA® logos, which are all trademarks owned by Acrotech Biopharma, LLC and its subsidiaries. All non-Acrotech owned trademarks, tradenames and service marks are the property of their respective owners.

    All Contents © Acrotech Biopharma, LLC. 2019. All rights reserved.

     

    Important Safety Information
    Click to Hide Advanced Floating Content
    Important Safety Information
    Warnings and Precautions

    Bone Marrow Suppression: For patients receiving EVOMELA as part of a conditioning regimen, myeloablation occurs in all patients. Do not begin the conditioning regimen if a stem cell product is not available for rescue. Monitor complete blood counts, provide supportive care for infections, anemia and thrombocytopenia until there is adequate hematopoietic recovery.

    See More